Evidence map›Paper›PMID 26479202›Full record

ArticleJournal of clinical virology : the official publication of the Pan American Society for Clinical Virology2015

Virome analysis of antiretroviral-treated HIV patients shows no correlation between T-cell activation and anelloviruses levels.

Linlin Li, Xutao Deng, Antonio Charlys Da Costa, Roberta Bruhn, Steven G Deeks, Eric Delwart

Open access · greenAbstract read
In one paragraph

Article in Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Linlin LiBlood Systems Research Institute, San Francisco, CA, USA; Department of Laboratory Medicine, University of California, San Francisco, CA, USA.
Xutao DengBlood Systems Research Institute, San Francisco, CA, USA; Department of Laboratory Medicine, University of California, San Francisco, CA, USA.
Antonio Charlys Da CostaBlood Systems Research Institute, San Francisco, CA, USA; Institute of Tropical Medicine, School of Medicine, University of São Paulo, São Paulo, Brazil.
Roberta BruhnBlood Systems Research Institute, San Francisco, CA, USA.
Steven G DeeksPositive Health Program, San Francisco General Hospital, San Francisco, CA, USA.
Eric DelwartBlood Systems Research Institute, San Francisco, CA, USA; Department of Laboratory Medicine, University of California, San Francisco, CA, USA. Electronic address: delwarte@medicine.ucsf.edu.
Blood Systems Research Institute · USUniversity of California, San Francisco · USSan Francisco General Hospital · US

Funding

UCSF CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTEUL1RR024131 · NCRR · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JOHNSTON, S. CLAIBORNE · 2006 to 2011
$111.2M
Unsolicited R24 for the CFAR-Network of Integrated Clinical Sciences, CNICSR24AI067039 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Michael S. Saag · 2006 to 2026
$99.4M
Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEVEN Grant DEEKS · 1988 to 2026
$93.6M
Viral reservoirs and sanctuaries in HAART - treated patients: role and mechanismsU19AI096109 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI DEEKS, STEVEN GRANT · 2011 to 2015
$29.5M
Metagenomic detection of emerging viruses in the blood supplyR01HL105770 · NHLBI · VITALANT · PI DELWART, ERIC L · 2011 to 2015
$2.4M
Preventing the Establishment of Enfuvirtide-resistance in the Latent ReservoirK24AI069994 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI DEEKS, STEVEN GRANT · 2007 to 2016
$1.5M
NCRR NIH HHS UL1 RR024131NHLBI NIH HHS R01 HL105770NHLBI NIH HHS R01HL105770NIAID NIH HHS AI069994NIAID NIH HHS AI096109NIAID NIH HHS K24 AI069994NIAID NIH HHS P30 AI027763NIAID NIH HHS R24 AI067039NIAID NIH HHS R24AI067039NIAID NIH HHS U19 AI096109
6 · The paper itself

Abstract

backgroundAbnormally high levels of T-cell activation can persist in HIV-infected subjects despite effective anti-retroviral therapy (ART) and has been associated with negative health outcomes. The nature of the antigenic drivers or other causes of this residual T-cell activation remain uncertain. Anelloviruses are universally acquired soon after birth, resulting in persistent viremia, and considered part of the commensal human virome. Reduced immunocompetence results in increased anellovirus levels.

objectivesTo test whether increased levels of anelloviruses or other viruses in plasma are associated with higher levels of persistent T-cell activation during ART. STUDY

designTwo amplification methods combined with next generation sequencing were used to detect all viruses and estimate relative anellovirus levels in plasma from 19 adults on effective ART who exhibited a wide range of T-cell activation levels.

resultsNucleic acids from HBV and HCV were detected in one patient each while pegivirus A (GBV-C) was found in three patients. Anellovirus DNA was detected in all patients with some individuals carrying up to eight different genotypes. Specific anellovirus genotypes or higher level of co-infections were not detected in subjects with higher levels of T-cell activation. No association was detected between relative plasma anellovirus DNA levels and the percentage of activated CD4 or CD8 T cells.

conclusionsHuman anelloviruses were detected in all HIV suppressed subjects, exhibited a wide range of viremia levels, and were genetically highly diverse. The level of persistent T-cell activation was not correlated with the level of viremia or genotypes present indicating that anellovirus antigens are unlikely to be a dominant source of antigens driving chronic T-cell activation.

Indexed as

Lymphocyte ActivationAdultAnelloviridaeAnti-Retroviral AgentsDNA Virus InfectionsFemaleHigh-Throughput Nucleotide SequencingHIV InfectionsHumansMaleMiddle AgedPolymerase Chain ReactionRetrospective StudiesT-LymphocytesViral LoadAnti-Retroviral AgentsAnellovirusHIVHLA-DR+CD38+T-cell activationTorque teno virusVirome

Identifiers

PMID26479202
PMCPMC4697764
OpenAlexW2180216372

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.